Skip to content

Clinical study of alfentanil combined with propofol for painless fiberoptic bronchoscopy in elderly patients

Clinical study of alfentanil combined with propofol for painless fiberoptic bronchoscopy in elderly patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089391
Enrollment
Unknown
Registered
2024-09-06
Start date
2021-01-07
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory depression

Interventions

Group A:Anesthesia induction: alfentanil 8ug/kg+ propofol 1.5mg/kg
Maintenance of anesthesia: continuous infusion of propofol 4-12mg/kg/h+alfentanil 0.25ug/kg/min.
Group R:Anesthesia induction: remifentanil 0.4ug/kg+ propofol 1.5 mg/kg
Maintenance of anesthesia: continuous infusion of propofol 4-12mg/kg/h+remifentanil 0.05ug/kg/min.

Sponsors

The First Affiliated Hospital of Nanhua University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Subjects undergoing painless fiberoptic bronchoscopy under general anesthesia; (2) 65-85 years old, male or female; (3) American Society of Anesthesiologists (ASA) grades II-III; (4)18kg/m2=BMI= 28kg/m2; (5) Voluntary participation in this study and signing of informed consent.

Exclusion criteria

Exclusion criteria: (1) Have a history of drug allergy related to the test; (2) Long-term use of analgesics or psychotropic drugs, and alcohol abusers; (3) Severe abnormality of liver and kidney function before operation; (4) Have a history of recovery from abnormal operation anesthesia; (5) There was uncontrolled hypertension in the past, or the systolic blood pressure > 180mmHg, or the diastolic blood pressure >110mmHg, or the preoperative heart rate < 60 beats/min; (6) Those who have bronchial asthma recently or are suffering from massive hemoptysis; (7) Severe stenosis of the main airway; (8) myasthenia gravis; (9) Patients with acute exacerbation of chronic obstructive pulmonary disease; (10) Suffering from esophageal reflux disease; (11) Predicted as a difficult airway; (12) Having participated in other drug trials within three months or unable to communicate effectively.

Design outcomes

Primary

MeasureTime frame
Incidence of respiratory depression;

Secondary

MeasureTime frame
low blood pressure;bradycardia;success rate of the first fiberoptic bronchoscopy;bronchoscopy score;endoscopist satisfaction;patients' willingness to receive treatment again;drug dosage;postoperative awakening time;time out of the operating room;vital signs;

Countries

China

Contacts

Public ContactXiaoling Hu

The First Affiliated Hospital of Nanhua University

291163028@qq.com+86 135 0734 7866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026